Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome

Neurobiology of Aging

Volumn 36, Issue 10, 2015, Pages 2907.e1-2907.e10

  Schupf, Nicole ^a,b   Lee, Annie ^a   Park, Naeun ^a   Dang, Lam Ha ^a   Pang, Deborah ^c   Yale, Alexander ^a   Oh, David Kyung Taek ^a   Krinsky McHale, Sharon J ^c   Jenkins, Edmund C ^c   Luchsinger, José A ^a   Zigman, Warren B ^c   Silverman, Wayne ^d   Tycko, Benjamin ^a   Kisselev, Sergey ^a   Clark, Lorraine ^a   Lee, Joseph H ^a,b  

^a Department of Medicine   (United States)

^b Vagelos College of Physicians and Surgeons   (United States)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Down syndrome; Genetics; Amyloid peptides

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TRANSCRIPTION FACTOR RUNX1; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; CALCIUM CHANNEL; CALHM1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; COPPER ZINC SUPEROXIDE DISMUTASE; DNA; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; SOD1 PROTEIN, HUMAN; SORCS1 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BACE2 GENE; CAHLM1 GENE; DOWN SYNDROME; ETHNICITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEREDITY; HIGH RISK POPULATION; HUMAN; IDE GENE; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; RISK FACTOR; RUNX1 GENE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOD1 GENE; SORCS1 GENE; BLOOD; DNA MICROARRAY; GENETIC ASSOCIATION STUDY; GENETICS; GENOTYPING TECHNIQUE; MIDDLE AGED; PROCEDURES; RISK; STATISTICAL MODEL;

ADULT; AGED; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CALCIUM CHANNELS; DNA; DOWN SYNDROME; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPING TECHNIQUES; HUMANS; LINEAR MODELS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; RISK; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE-1;

EID: 84940954875     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.06.020     Document Type: Article

References (104)

1. Abraham R., Myers A., Wavrant-DeVrieze F., Hamshere M.L., Thomas H.V., Marshall H., Compton D., Spurlock G., Turic D., Hoogendoorn B., Kwon J.M., Petersen R.C., Tangalos E., Norton J., Morris J.C., Bullock R., Liolitsa D., Lovestone S., Hardy J., Goate A., O'Donovan M., Williams J., Owen M.J., Jones L. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum. Genet. 2001, 109:646-652.
2. Aylward E.H., Burt D.B., Thorpe L.U., Lai F., Dalton A. Diagnosis of dementia in individuals with intellectual disability. J. Intellect. Disabil. Res. 1997, 41(Pt 2):152-164.
3. Bali J., Gheinani A.H., Zurbriggen S., Rajendran L. Role of genes linked to sporadic Alzheimer's disease risk in the production of beta-amyloid peptides. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:15307-15311.
4. Beecham G.W., Schnetz-Boutaud N., Haines J.L., Pericak-Vance M.A. CALHM1 polymorphism is not associated with late-onset Alzheimer disease. Ann. Hum. Genet. 2009, 73(Pt 3):379-381.
5. Benitez B.A., Karch C.M., Cai Y., Jin S.C., Cooper B., Carrell D., Bertelsen S., Chibnik L., Schneider J.A., Bennett D.A., Fagan A.M., Holtzman D., Morris J.C., Goate A.M., Cruchaga C. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-epsilon4 carriers. PLoS Genet. 2013, 9:e1003685. Alzheimer's Disease Neuroimaging, I, Genetic, environmental risk for Alzheimer's disease consortium, GGenetic, environmental risk for Alzheimer's disease consortium, G.
6. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B (Methodological) 1995, 57:289-300.
7. Benjamini Y., Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 2001, 29:1165-1188.
8. Bernstein H.G., Ansorge S., Riederer P., Reiser M., Frolich L., Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci. Lett. 1999, 263:161-164.
9. Bertram L., Schjeide B.M., Hooli B., Mullin K., Hiltunen M., Soininen H., Ingelsson M., Lannfelt L., Blacker D., Tanzi R.E. No association between CALHM1 and Alzheimer's disease risk. Cell 2008, 135:993-994.
10. Bertram L., Tanzi R.E. The genetics of Alzheimer's disease. Prog. Mol. Biol. Transl. Sci. 2012, 107:79-100.
11. Blasko I., Kemmler G., Jungwirth S., Wichart I., Krampla W., Weissgram S., Jellinger K., Tragl K.H., Fischer P. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am. J. Geriatr. Psychiatry 2010, 18:973-982.
12. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2:605-613.
13. Boada M., Antunez C., Lopez-Arrieta J., Galan J.J., Moron F.J., Hernandez I., Marin J., Martinez-Lage P., Alegret M., Carrasco J.M., Moreno C., Real L.M., Gonzalez-Perez A., Tarraga L., Ruiz A. CALHM1 P86L polymorphism is associated with late-onset Alzheimer's disease in a recessive model. J. Alzheimers Dis. 2010, 20:247-251.
14. Boussaha M., Hannequin D., Verpillat P., Brice A., Frebourg T., Campion D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci. Lett. 2002, 329:121-123.
15. Burt D.B., Aylward E.H. Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. J. Intellect. Disabil. Res. 2000, 44(Pt 2):175-180.
16. Carrasquillo M.M., Belbin O., Zou F., Allen M., Ertekin-Taner N., Ansari M., Wilcox S.L., Kashino M.R., Ma L., Younkin L.H., Younkin S.G., Younkin C.S., Dincman T.A., Howard M.E., Howell C.C., Stanton C.M., Watson C.M., Crump M., Vitart V., Hayward C., Hastie N.D., Rudan I., Campbell H., Polasek O., Brown K., Passmore P., Craig D., McGuinness B., Todd S., Kehoe P.G., Mann D.M., Smith A.D., Beaumont H., Warden D., Holmes C., Heun R., Kolsch H., Kalsheker N., Pankratz V.S., Dickson D.W., Graff-Radford N.R., Petersen R.C., Wright A.F., Younkin S.G., Morgan K. Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. PLoS One 2010, 5:e8764.
17. Chapman J., Rees E., Harold D., Ivanov D., Gerrish A., Sims R., Hollingworth P., Stretton A., Holmans P., Owen M.J., ODonovan M.C., Williams J., Kirov G., Consortium, G. A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk. Hum. Mol. Genet. 2013, 22:816-824. Consortium, G.
18. Cheng D., Noble J., Tang M.X., Schupf N., Mayeux R., Luchsinger A. Type 2 diabetes and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2011, 31:424-430.
19. Chouraki V., De Bruijn R.F., Chapuis J., Bis J.C., Reitz C., Schraen S., Ibrahim-Verbaas C.A., Grenier-Boley B., Delay C., Rogers R., Demiautte F., Mounier A., Fitzpatrick A.L., Berr C., Dartigues J.F., Uitterlinden A.G., Hofman A., Breteler M., Becker J.T., Lathrop M., Schupf N., Alperovitch A., Mayeux R., van Duijn C.M., Buee L., Amouyel P., Lopez O.L., Ikram M.A., Tzourio C., Lambert J.C. A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly. Mol. Psychiatry 2014, 19:1326-1335. Alzheimer's Disease Neuroimaging, I.
20. Clee S.M., Yandell B.S., Schueler K.M., Rabaglia M.E., Richards O.C., Raines S.M., Kabara E.A., Klass D.M., Mui E.T., Stapleton D.S., Gray-Keller M.P., Young M.B., Stoehr J.P., Lan H., Boronenkov I., Raess P.W., Flowers M.T., Attie A.D. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat. Genet. 2006, 38:688-693.
21. Conti E., Galimberti G., Piazza F., Raggi M.E., Ferrarese C. Increased soluble APPalpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from down syndrome patients. Alzheimer Dis. Assoc. Disord. 2010, 24:96-100.
22. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 2003, 162:313-319.
23. Coppus A.M., Schuur M., Vergeer J., Janssens A.C., Oostra B.A., Verbeek M.M., van Duijn C.M. Plasma beta amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol. Aging 2012, 33:1988-1994.
24. Cummings B.J., Cotman C.W. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995, 346:1524-1528.
25. de Bakker P.I. Selection and evaluation of Tag-SNPs using Tagger and HapMap. Cold Spring Harb. Protoc. 2009, 2009. pdb ip67.
26. Dickinson M.J., Singh I. Down's syndrome, dementia, and superoxide dismutase. Br. J. Psychiatry 1993, 162:811-817.
27. 2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008, 133:1149-1161.
28. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
29. Fagan A.M., Mintun M.A., Shah A.R., Aldea P., Roe C.M., Mach R.H., Marcus D., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 2009, 1:371-380.
30. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
31. Fakhrai-Rad H., Nikoshkov A., Kamel A., Fernstrom M., Zierath J.R., Norgren S., Luthman H., Galli J. Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum. Mol. Genet. 2000, 9:2149-2158.
32. Florez J.C., Wiltshire S., Agapakis C.M., Burtt N.P., de Bakker P.I., Almgren P., Bengtsson Bostrom K., Tuomi T., Gaudet D., Daly M.J., Hirschhorn J.N., McCarthy M.I., Altshuler D., Groop L. High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people. Diabetes 2006, 55:128-135.
33. Fonseca C.T., Amaral D.M., Ribeiro M.G., Beserra I.C., Guimaraes M.M. Insulin resistance in adolescents with Down syndrome: a cross-sectional study. BMC Endocr. Disord. 2005, 5:6.
34. Furuta A., Price D.L., Pardo C.A., Troncoso J.C., Xu Z.S., Taniguchi N., Martin L.J. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am. J. Pathol. 1995, 146:357-367.
35. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Cance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
36. Goodarzi M.O., Lehman D.M., Taylor K.D., Guo X., Cui J., Quinones M.J., Clee S.M., Yandell B.S., Blangero J., Hsueh W.A., Attie A.D., Stern M.P., Rotter J.I. SORCS1: a novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes 2007, 56:1922-1929.
37. Groves C.J., Wiltshire S., Smedley D., Owen K.R., Frayling T.M., Walker M., Hitman G.A., Levy J.C., O'Rahilly S., Menzel S., Hattersley A.T., McCarthy M.I. Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility. Diabetes 2003, 52:1300-1305.
38. Guerreiro R.J., Gustafson D.R., Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol. Aging. 2012, 33:437-456.
39. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007, 23:316-320.
40. Head E., Doran E., Nistor M., Hill M., Schmitt F.A., Haier R.J., Lott I.T. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J. Alzheimers Dis. 2011, 23:399-409.
41. Head E., Silverman W., Patterson D., Lott I.T. Aging and Down syndrome. Curr. Gerontol. Geriatr. Res. 2012, 2012:412536.
42. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 1990, 31:545-548.
43. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.C., Carrasquillo M.M., Abraham R., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Jones N., Stretton A., Thomas C., Richards A., Ivanov D., Widdowson C., Chapman J., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Beaumont H., Warden D., Wilcock G., Love S., Kehoe P.G., Hooper N.M., Vardy E.R., Hardy J., Mead S., Fox N.C., Rossor M., Collinge J., Maier W., Jessen F., Ruther E., Schurmann B., Heun R., Kolsch H., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Gallacher J., Hull M., Rujescu D., Giegling I., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Pankratz V.S., Sando S.B., Aasly J.O., Barcikowska M., Wszolek Z.K., Dickson D.W., Graff-Radford N.R., Petersen R.C., van Duijn C.M., Breteler M.M., Ikram M.A., DeStefano A.L., Fitzpatrick A.L., Lopez O., Launer L.J., Seshadri S., Berr C., Campion D., Epelbaum J., Dartigues J.F., Tzourio C., Alperovitch A., Lathrop M., Feulner T.M., Friedrich P., Riehle C., Krawczak M., Schreiber S., Mayhaus M., Nicolhaus S., Wagenpfeil S., Steinberg S., Stefansson H., Stefansson K., Snaedal J., Bjornsson S., Jonsson P.V., Chouraki V., Genier-Boley B., Hiltunen M., Soininen H., Combarros O., Zelenika D., Delepine M., Bullido M.J., Pasquier F., Mateo I., Frank-Garcia A., Porcellini E., Hanon O., Coto E., Alvarez V., Bosco P., Siciliano G., Mancuso M., Panza F., Solfrizzi V., Nacmias B., Sorbi S., Bossu P., Piccardi P., Arosio B., Annoni G., Seripa D., Pilotto A., Scarpini E., Galimberti D., Brice A., Hannequin D., Licastro F., Jones L., Holmans P.A., Jonsson T., Riemenschneider M., Morgan K., Younkin S.G., Owen M.J., O'Donovan M., Amouyel P., Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435. Alzheimer's Disease Neuroimaging, I, Consortium, CConsortium, C, Consortium, EConsortium, E.
44. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
45. Jones E.L., Hanney M., Francis P.T., Ballard C.G. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci. Lett. 2009, 451:162-164.
46. Jones E.L., Mok K., Hanney M., Harold D., Sims R., Williams J., Ballard C. Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiol. Aging 2013, 34:2441.e1-2441.e5.
47. Jun G., Naj A.C., Beecham G.W., Wang L.S., Buros J., Gallins P.J., Buxbaum J.D., Ertekin-Taner N., Fallin M.D., Friedland R., Inzelberg R., Kramer P., Rogaeva E., St George-Hyslop P., Cantwell L.B., Dombroski B.A., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Lunetta K.L., Martin E.R., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Beekly D., Cupples L.A., Hakonarson H., Kukull W., Foroud T.M., Haines J., Mayeux R., Farrer L.A., Pericak-Vance M.A., Schellenberg G.D. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 2010, 67:1473-1484. Alzheimer's Disease Genetics, C.
48. Karamohamed S., Demissie S., Volcjak J., Liu C., Heard-Costa N., Liu J., Shoemaker C.M., Panhuysen C.I., Meigs J.B., Wilson P., Atwood L.D., Cupples L.A., Herbert A. Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes 2003, 52:1562-1567.
49. Kim S., Swaminathan S., Shen L., Risacher S.L., Nho K., Foroud T., Shaw L.M., Trojanowski J.Q., Potkin S.G., Huentelman M.J., Craig D.W., DeChairo B.M., Aisen P.S., Petersen R.C., Weiner M.W., Saykin A.J. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79. Alzheimer's Disease Neuroimaging, I.
50. Kimura R., Kamino K., Yamamoto M., Nuripa A., Kida T., Kazui H., Hashimoto R., Tanaka T., Kudo T., Yamagata H., Tabara Y., Miki T., Akatsu H., Kosaka K., Funakoshi E., Nishitomi K., Sakaguchi G., Kato A., Hattori H., Uema T., Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum. Mol. Genet. 2007, 16:15-23.
51. Kurochkin I.V., Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 1994, 345:33-37.
52. Kwak S.H., Cho Y.M., Moon M.K., Kim J.H., Park B.L., Cheong H.S., Shin H.D., Jang H.C., Kim S.Y., Lee H.K., Park K.S. Association of polymorphisms in the insulin-degrading enzyme gene with type 2 diabetes in the Korean population. Diabetes Res. Clin. Pract. 2008, 79:284-290.
53. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
54. Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., Russo G., Thorton-Wells T.A., Jones N., Smith A.V., Chouraki V., Thomas C., Ikram M.A., Zelenika D., Vardarajan B.N., Kamatani Y., Lin C.F., Gerrish A., Schmidt H., Kunkle B., Dunstan M.L., Ruiz A., Bihoreau M.T., Choi S.H., Reitz C., Pasquier F., Cruchaga C., Craig D., Amin N., Berr C., Lopez O.L., De Jager P.L., Deramecourt V., Johnston J.A., Evans D., Lovestone S., Letenneur L., Moron F.J., Rubinsztein D.C., Eiriksdottir G., Sleegers K., Goate A.M., Fievet N., Huentelman M.W., Gill M., Brown K., Kamboh M.I., Keller L., Barberger-Gateau P., McGuiness B., Larson E.B., Green R., Myers A.J., Dufouil C., Todd S., Wallon D., Love S., Rogaeva E., Gallacher J., St George-Hyslop P., Clarimon J., Lleo A., Bayer A., Tsuang D.W., Yu L., Tsolaki M., Bossu P., Spalletta G., Proitsi P., Collinge J., Sorbi S., Sanchez-Garcia F., Fox N.C., Hardy J., Deniz Naranjo M.C., Bosco P., Clarke R., Brayne C., Galimberti D., Mancuso M., Matthews F., Moebus S., Mecocci P., Del Zompo M., Maier W., Hampel H., Pilotto A., Bullido M., Panza F., Caffarra P., Nacmias B., Gilbert J.R., Mayhaus M., Lannefelt L., Hakonarson H., Pichler S., Carrasquillo M.M., Ingelsson M., Beekly D., Alvarez V., Zou F., Valladares O., Younkin S.G., Coto E., Hamilton-Nelson K.L., Gu W., Razquin C., Pastor P., Mateo I., Owen M.J., Faber K.M., Jonsson P.V., Combarros O., O'Donovan M.C., Cantwell L.B., Soininen H., Blacker D., Mead S., Mosley T.H., Bennett D.A., Harris T.B., Fratiglioni L., Holmes C., de Bruijn R.F., Passmore P., Montine T.J., Bettens K., Rotter J.I., Brice A., Morgan K., Foroud T.M., Kukull W.A., Hannequin D., Powell J.F., Nalls M.A., Ritchie K., Lunetta K.L., Kauwe J.S., Boerwinkle E., Riemenschneider M., Boada M., Hiltuenen M., Martin E.R., Schmidt R., Rujescu D., Wang L.S., Dartigues J.F., Mayeux R., Tzourio C., Hofman A., Nothen M.M., Graff C., Psaty B.M., Jones L., Haines J.L., Holmans P.A., Lathrop M., Pericak-Vance M.A., Launer L.J., Farrer L.A., van Duijn C.M., Van Broeckhoven C., Moskvina V., Seshadri S., Williams J., Schellenberg G.D., Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013, 45:1452-1458. European Alzheimer's Disease, I, Genetic, Environmental Risk in Alzheimer's, DGenetic, Environmental Risk in Alzheimer's, D, Alzheimer's Disease Genetic, CAlzheimer's Disease Genetic, C, Cohorts for, H., Aging Research in Genomic, ECohorts for, H., Aging Research in Genomic, E.
55. Lambert J.C., Schraen-Maschke S., Richard F., Fievet N., Rouaud O., Berr C., Dartigues J.F., Tzourio C., Alperovitch A., Buee L., Amouyel P. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 2009, 73:847-853.
56. Lambert J.C., Sleegers K., Gonzalez-Perez A., Ingelsson M., Beecham G.W., Hiltunen M., Combarros O., Bullido M.J., Brouwers N., Bettens K., Berr C., Pasquier F., Richard F., Dekosky S.T., Hannequin D., Haines J.L., Tognoni G., Fievet N., Dartigues J.F., Tzourio C., Engelborghs S., Arosio B., Coto E., De Deyn P., Del Zompo M., Mateo I., Boada M., Antunez C., Lopez-Arrieta J., Epelbaum J., Schjeide B.M., Frank-Garcia A., Giedraitis V., Helisalmi S., Porcellini E., Pilotto A., Forti P., Ferri R., Delepine M., Zelenika D., Lathrop M., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Ravaglia G., Valdivieso F., Vepsalainen S., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Hanon O., Piccardi P., Annoni G., Mann D., Marambaud P., Seripa D., Galimberti D., Tanzi R.E., Bertram L., Lendon C., Lannfelt L., Licastro F., Campion D., Pericak-Vance M.A., Soininen H., Van Broeckhoven C., Alperovitch A., Ruiz A., Kamboh M.I., Amouyel P. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J. Alzheimers Dis. 2010, 22:247-255.
57. Lane R.F., Raines S.M., Steele J.W., Ehrlich M.E., Lah J.A., Small S.A., Tanzi R.E., Attie A.D., Gandy S. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J. Neurosci. 2010, 30:13110-13115.
58. Lane R.F., Steele J.W., Cai D., Ehrlich M.E., Attie A.D., Gandy S. Protein sorting motifs in the cytoplasmic tail of SorCS1 control generation of Alzheimer's amyloid-beta peptide. J. Neurosci. 2013, 33:7099-7107.
59. Lee J.H., Chulikavit M., Pang D., Zigman W.B., Silverman W., Schupf N. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. Neurosci. Lett. 2007, 425:105-109.
60. Lott I.T., Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:172-178.
61. Lott I.T., Head E., Doran E., Busciglio J. Beta-amyloid, oxidative stress and down syndrome. Curr. Alzheimer Res. 2006, 3:521-528.
62. Luchsinger J.A., Tang M.-X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
63. Margallo-Lana M., Morris C.M., Gibson A.M., Tan A.L., Kay D.W., Tyrer S.P., Moore B.P., Ballard C.G. Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology 2004, 62:1996-1998.
64. Markesbery W.R., Lovell M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch. Neurol. 2007, 64:954-956.
65. Matsuoka Y., Andrews H.F., Becker A.G., Gray A.J., Mehta P.D., Sano M.C., Dalton A.J., Aisen P.S. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis. Assoc. Disord. 2009, 23:315-318.
66. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185-1190.
67. Mayeux R., Tang M.X., Jacobs D.M., Manly J., Bell K., Merchant C., Small S.A., Stern Y., Wisniewski H.M., Mehta P.D. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 1999, 46:412-416.
68. Mehta P.D., Dalton A.J., Mehta S.P., Kim K.S., Sersen E.A., Wisniewski H.M. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci. Lett. 1998, 241:13-16.
69. Miners J.S., van Helmond Z., Raiker M., Love S., Kehoe P.G. ACE variants and association with brain Abeta levels in Alzheimer's disease. Am. J. Transl. Res. 2010, 3:73-80.
70. Minster R.L., Demirci F.Y., DeKosky S.T., Kamboh M.I. No association between CALHM1 variation and risk of Alzheimer disease. Hum. Mutat. 2009, 30:E566-E569.
71. Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., Larson E.B., Bird T.D., Boeve B.F., Graff-Radford N.R., De Jager P.L., Evans D., Schneider J.A., Carrasquillo M.M., Ertekin-Taner N., Younkin S.G., Cruchaga C., Kauwe J.S., Nowotny P., Kramer P., Hardy J., Huentelman M.J., Myers A.J., Barmada M.M., Demirci F.Y., Baldwin C.T., Green R.C., Rogaeva E., St George-Hyslop P., Arnold S.E., Barber R., Beach T., Bigio E.H., Bowen J.D., Boxer A., Burke J.R., Cairns N.J., Carlson C.S., Carney R.M., Carroll S.L., Chui H.C., Clark D.G., Corneveaux J., Cotman C.W., Cummings J.L., DeCarli C., DeKosky S.T., Diaz-Arrastia R., Dick M., Dickson D.W., Ellis W.G., Faber K.M., Fallon K.B., Farlow M.R., Ferris S., Frosch M.P., Galasko D.R., Ganguli M., Gearing M., Geschwind D.H., Ghetti B., Gilbert J.R., Gilman S., Giordani B., Glass J.D., Growdon J.H., Hamilton R.L., Harrell L.E., Head E., Honig L.S., Hulette C.M., Hyman B.T., Jicha G.A., Jin L.W., Johnson N., Karlawish J., Karydas A., Kaye J.A., Kim R., Koo E.H., Kowall N.W., Lah J.J., Levey A.I., Lieberman A.P., Lopez O.L., Mack W.J., Marson D.C., Martiniuk F., Mash D.C., Masliah E., McCormick W.C., McCurry S.M., McDavid A.N., McKee A.C., Mesulam M., Miller B.L., Miller C.A., Miller J.W., Parisi J.E., Perl D.P., Peskind E., Petersen R.C., Poon W.W., Quinn J.F., Rajbhandary R.A., Raskind M., Reisberg B., Ringman J.M., Roberson E.D., Rosenberg R.N., Sano M., Schneider L.S., Seeley W., Shelanski M.L., Slifer M.A., Smith C.D., Sonnen J.A., Spina S., Stern R.A., Tanzi R.E., Trojanowski J.Q., Troncoso J.C., Van Deerlin V.M., Vinters H.V., Vonsattel J.P., Weintraub S., Welsh-Bohmer K.A., Williamson J., Woltjer R.L., Cantwell L.B., Dombroski B.A., Beekly D., Lunetta K.L., Martin E.R., Kamboh M.I., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Hakonarson H., Kukull W.A., Foroud T.M., Haines J.L., Mayeux R., Pericak-Vance M.A., Farrer L.A., Schellenberg G.D. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
72. Naslund J., Haroutonian V., Mohs R., Davis K., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
73. Nowotny P., Hinrichs A.L., Smemo S., Kauwe J.S., Maxwell T., Holmans P., Hamshere M., Turic D., Jehu L., Hollingworth P., Moore P., Bryden L., Myers A., Doil L.M., Tacey K.M., Gibson A.M., McKeith I.G., Perry R.H., Morris C.M., Thal L., Morris J.C., O'Donovan M.C., Lovestone S., Grupe A., Hardy J., Owen M.J., Williams J., Goate A. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 136B:62-68.
74. Ozturk A., DeKosky S.T., Kamboh M.I. Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease. Neurosci. Lett. 2006, 406:265-269.
75. Patel A., Rees S.D., Kelly M.A., Bain S.C., Barnett A.H., Thalitaya D., Prasher V.P. Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome. Neurosci. Lett. 2011, 487:144-148.
76. Pomara N., Willoughby L.M., Sidtis J.J., Mehta P.D. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am. J. Geriatr. Psychiatry 2005, 13:914-917.
77. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
78. Qin W., Jia J. Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. Eur. J. Neurosci. 2008, 27:2425-2432.
79. Qiu W.Q., Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging. 2006, 27:190-198.
80. Reitz C., Cheng R., Rogaeva E., Lee J.H., Tokuhiro S., Zou F., Bettens K., Sleegers K., Tan E.K., Kimura R., Shibata N., Arai H., Kamboh M.I., Prince J.A., Maier W., Riemenschneider M., Owen M., Harold D., Hollingworth P., Cellini E., Sorbi S., Nacmias B., Takeda M., Pericak-Vance M.A., Haines J.L., Younkin S., Williams J., van Broeckhoven C., Farrer L.A., St George-Hyslop P.H., Mayeux R. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch. Neurol. 2011, 68:99-106. Genetic, Environmental Risk in Alzheimer Disease, C.
81. Reitz C., Cheng R., Schupf N., Lee J.H., Mehta P.D., Rogaeva E., St George-Hyslop P., Mayeux R. Association between variants in IDE-KIF11-HHEX and plasma amyloid beta levels. Neurobiol. Aging 2012, 33:199.e13-199.e17.
82. Reitz C., Tokuhiro S., Clark L.N., Conrad C., Vonsattel J.P., Hazrati L.N., Palotas A., Lantigua R., Medrano M., Jiménez Velázquez I., Vardarajan B., Simkin I., Haines J.L., Pericak-Vance M.A., Farrer L.A., Lee J.H., Rogaeva E., George-Hyslop P.S., Mayeux R. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann. Neurol. 2011, 69:47-64.
83. Reynolds G.P., Cutts A.J. Free radical damage in Down's syndrome brain. Biochem. Soc. Trans. 1993, 21:221S.
84. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K.L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L.A., Cuenco K.T., Green R.C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R.P., Inzelberg R., Hampe W., Bujo H., Song Y.Q., Andersen O.M., Willnow T.E., Graff-Radford N., Petersen R.C., Dickson D., Der S.D., Fraser P.E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L.A., St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39:168-177.
85. Rudovich N., Pivovarova O., Fisher E., Fischer-Rosinsky A., Spranger J., Mohlig M., Schulze M.B., Boeing H., Pfeiffer A.F. Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes. J. Mol. Med. (Berl.). 2009, 87:1145-1151.
86. Sakai A., Ujike H., Nakata K., Takehisa Y., Imamura T., Uchida N., Kanzaki A., Yamamoto M., Fujisawa Y., Okumura K., Kuroda S. No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 125B:87-91.
87. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
88. Schupf N., Patel B., Silverman W., Zigman W.B., Zhong N., Tycko B., Mehta P.D., Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci. Lett. 2001, 301:199-203.
89. Schupf N., Patel B., Pang D., Zigman W.B., Silverman W., Mehta P.D., Mayeux R. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch. Neurol. 2007, 64:1007-1013.
90. Schupf N., Tang M.X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14052-14057.
91. Schupf N., Zigman W.B., Tang M.X., Pang D., Mayeux R., Mehta P., Silverman W. Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology 2010, 75:1639-1644.
92. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
93. Shulman J.M., Chen K., Keenan B.T., Chibnik L.B., Fleisher A., Thiyyagura P., Roontiva A., McCabe C., Patsopoulos N.A., Corneveaux J.J., Yu L., Huentelman M.J., Evans D.A., Schneider J.A., Reiman E.M., De Jager P.L., Bennett D.A. Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol. 2013, 70:1150-1157.
94. Silverman W., Schupf N., Zigman W., Devenny D., Miezejeski C., Schubert R., Ryan R. Dementia in adults with mental retardation: assessment at a single point in time. Am. J. Ment. Retard. 2004, 109:111-125.
95. Singth I., Dickinson M. Down syndrome, dementia and superoxide dismutase. Down Syndrome and Alzheimer's Disease: Biological Correlates 2006, 79-85. Raadcliffe, Oxford. V. Prasher (Ed.).
96. Teller J.K., Russo C., DeBusk L.M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D.M., Tabaton M., Gambetti P. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 1996, 2:93-95.
97. Tokuda T., Fukushima T., Ikeda S., Sekijima Y., Shoji S., Yanagisawa N., Tamaoka A. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann. Neurol. 1997, 41:271-273.
98. Toledo J.B., Shaw L.M., Trojanowski J.Q. Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker. Alzheimers Res. Ther. 2013, 5:8.
99. Vardarajan B.N., Bruesegem S.Y., Harbour M.E., St George-Hyslop P., Seaman M.N., Farrer L.A. Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiol. Aging 2012, 33:2231e15-2231e30.
100. Vepsalainen S., Parkinson M., Helisalmi S., Mannermaa A., Soininen H., Tanzi R.E., Bertram L., Hiltunen M. Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J. Med. Genet. 2007, 44:606-608.
101. Younkin S.G. The AAP and PS1/2 mutations linked to early onset familial Alzheimer's disease increase the extracellular concentration and A beta 1-42(43). Rinsho Shinkeigaku. 1997, 37:1099.
102. Zhao Z., Xiang Z., Haroutunian V., Buxbaum J.D., Stetka B., Pasinetti G.M. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging. 2007, 28:824-830.
103. Zis P., Dickinson M., Shende S., Walker Z., Strydom A. Oxidative stress and memory decline in adults with Down syndrome: longitudinal study. J. Alzheimers Dis. 2012, 31:277-283.
104. Zuo X., Jia J. Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease. Brain Res. 2009, 1249:1-8.